Texas A&M Researcher Receives Inaugural Chancellor’s Innovation Award

Scott Dindot, PhD

Dr. Scott Dindot, an associate professor in the Texas A&M School of Veterinary Medicine & Biomedical Sciences’ Department of Veterinary Pathobiology and in the School of Medicine’s Department of Molecular & Cellular Medicine, was named the inaugural Chancellor’s Innovation Award recipient at The Texas A&M University System Innovation Luncheon.

The Chancellor’s Innovation Award recognizes one employee from an institution within the Texas A&M University System who has made a remarkable achievement through their discovery and invention.

Dindot works with a specific gene implicated in a rare disorder, Angelman syndrome (AS), and has developed a targeted drug therapy – now known as GTX-102 – that “goes after the heart of the condition,” according to Dindot. His drug therapy was the subject of a $75 million acquisition by Ultragenyx Pharmaceutical, Inc., which is leading the continued development of the treatment.